Investigating the mechanism of impact of the Quality Premium initiative on antibiotic prescribing in primary care practices in England: a study protocol.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
03 09 2019
Historique:
entrez: 5 9 2019
pubmed: 5 9 2019
medline: 29 8 2020
Statut: epublish

Résumé

The persistent development and spread of resistance to antibiotics remain an important public health concern in the UK and globally. About 74% of antibiotics prescribed in England in 2016 was in primary care. The Quality Premium (QP) initiative that rewards Clinical Commissioning Groups (CCGs) financially based on the quality of specific health services commissioned is one of the National Health Service (NHS) England interventions to reduce antimicrobial resistance through reduced prescribing. Emerging evidence suggests a reduction in antibiotic prescribing in primary care practices in the UK following QP initiative. This study aims to investigate the mechanism of impact of this high-cost health-system level intervention on antibiotic prescribing in primary care practices in England. The study will constitute secondary analyses of antibiotic prescribing data for almost all primary care practices in England from the NHS England Antibiotic Quality Premium Monitoring Dashboard and OpenPrescribing covering the period 2013 to 2018. The primary outcome is the number of antibiotic items per Specific Therapeutic group Age-sex Related Prescribing Unit (STAR-PU) prescribed monthly in each practice or CCG. We will first conduct an interrupted time series using ordinary least square regression method to examine whether antibiotic prescribing rate in England has changed over time, and how such changes, if any, are associated with QP implementation. Single and sequential multiple-mediator models using a unified approach for the natural direct and indirect effects will be conducted to investigate the relationship between QP initiative, the potential mediators and antibiotic prescribing rate with adjustment for practice and CCG characteristics. This study will use secondary data that are anonymised and obtained from studies that have either undergone ethical review or generated data from routine collection systems. Multiple channels will be used in disseminating the findings from this study to academic and non-academic audiences.

Identifiants

pubmed: 31481371
pii: bmjopen-2019-030093
doi: 10.1136/bmjopen-2019-030093
pmc: PMC6731864
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e030093

Subventions

Organisme : Department of Health
ID : CDF-2016-09-015
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Prev Sci. 2000 Dec;1(4):173-81
pubmed: 11523746
Int J Epidemiol. 2005 Feb;34(1):215-20
pubmed: 15333621
Br J Gen Pract. 2006 Mar;56(524):183-90
pubmed: 16536958
Epidemiology. 2006 May;17(3):276-84
pubmed: 16617276
Annu Rev Psychol. 2007;58:593-614
pubmed: 16968208
Br J Gen Pract. 2007 Oct;57(543):785-92
pubmed: 17925135
Ir Med J. 2007 Oct;100(9):598-601
pubmed: 18196886
BMJ. 2009 Jun 29;338:b2393
pubmed: 19564179
N Engl J Med. 2009 Jul 23;361(4):368-78
pubmed: 19625717
BMJ. 2010 May 18;340:c2096
pubmed: 20483949
J Antimicrob Chemother. 2011 Oct;66(10):2215-23
pubmed: 21764827
J Epidemiol Community Health. 2012 Dec;66(12):1182-6
pubmed: 22577181
Am J Epidemiol. 2012 Aug 1;176(3):190-5
pubmed: 22781427
BMC Infect Dis. 2014 Jan 09;14:13
pubmed: 24405683
Epidemiol Methods. 2014 Jan;2(1):95-115
pubmed: 25580377
Fam Pract. 2015 Aug;32(4):401-7
pubmed: 25911505
Lancet. 2016 Apr 23;387(10029):1743-52
pubmed: 26898856
N C Med J. 2016 Sep-Oct;77(5):346-9
pubmed: 27621347
Fam Pract. 2018 Jul 23;35(4):461-467
pubmed: 29300965
J Antimicrob Chemother. 2018 Feb 1;73(suppl_2):ii27-ii35
pubmed: 29490059
J Antimicrob Chemother. 2018 May 1;73(5):1423-1432
pubmed: 29514268
Br J Gen Pract. 2018 Sep;68(674):e633-e645
pubmed: 29914880
J Antimicrob Chemother. 2018 Oct 1;73(10):2883-2892
pubmed: 29955785
BMJ. 1997 Nov 8;315(7117):1211-4
pubmed: 9393228

Auteurs

Philip Emeka Anyanwu (PE)

Global Digital Health Unit, Department of Primary Care and Public Health, Imperial College London, London, UK anyanwuphilipemeka@gmail.com.

Sarah Tonkin-Crine (S)

Nuffield Department of Primary Care Sciences, University of Oxford, Oxford, UK.
NIHR Health Protection Research Unit, Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford, UK.

Aleksandra Borek (A)

Nuffield Department of Primary Care Sciences, University of Oxford, Oxford, UK.

Ceire Costelloe (C)

Global Digital Health Unit, Department of Primary Care and Public Health, Imperial College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH